Fibrogen Inc CS (FGEN) Stock Price, Quote & News

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 978 1200

Fax: 415 978 1902

Website: www.fibrogen.com

Address:

350 Bay Street, Suite 10 #6009, San Francisco, United States

Value10 Sep. 12 at 1:19 PM

$FGEN This SEC settlement (below), was only announced yesterday, so it is not really ”old news” as some say. Google the full document, it is worth reading… it tells the historical facts of what went wrong and who did it. Mostly, this is why FGEN lost all credibility and lost billions of dollars in stock value. ROX may have previously been approved in the USA, but with a “black-box warning” on safety, but still would have been valuable. It is difficult to know if the FDA will forget this betrayal, and lets FGEN use ROX for other medical issues in the USA. The Billion Dollar question.

2 · Reply

MaxMiamiFl Sep. 12 at 1:14 PM

$FGEN $11.30 to $14.00.....GO to $14 !!!! That's one of my exits.

0 · Reply

MaxMiamiFl Sep. 12 at 1:11 PM

$FGEN Lets go!

0 · Reply

Ctgf Sep. 12 at 4:03 AM

$FGEN At least this gives current management an opportunity to move forward. They are blaming everything on Peony Yu, whereas I expect that previous CEO Neff created this toxic environment.

2 · Reply

Red6213 Sep. 11 at 5:43 PM

$FGEN I am out. Held for 7 months expecting it would go up after AZN china close out, but nothing changed here and now doesnt have hope that it will rise and had to exit with loss. Looks like nobody is interested in their clinical pipeline and I think everybody feels that company is only going to burn cash every quarter until it completely depletes and go to ashes/pennies.

4 · Reply

DipnRiptrader Sep. 11 at 5:02 PM

$FGEN Adding some of this. Ideally want a lower price but think this will do well overall.

1 · Reply

Value10 Sep. 11 at 4:43 PM

$FGEN Really Nice Volume… came in all at once… pushed it up.

1 · Reply

MaxMiamiFl Sep. 11 at 12:58 PM

$FGEN Nothing new. same red BS

0 · Reply

NVDAMillionaire Sep. 11 at 6:26 AM

$FGEN Really good write-up that perfectly summarizes FGEN's present situation. So if you want to bring your FGEN knowledge up to date or just discover FGEN, this is required reading. https://beyondspx.com/quote/FGEN/analysis/fibrogen-s-strategic-rebirth-unlocking-oncology-and-mds-potential-nasdaq-fgen

1 · Reply

Value10 Sep. 9 at 8:27 PM

$FGEN FGEN is not a “trading stock”, it never has been. So, all that frustration on daily minimal movement, and falling for no reason… that pain is going to continue daily… ongoing. There are plenty of other daily trading stocks; Tesla, Nvidia, etc… Go do those stocks if FGEN frustrates you daily. Avoid the pain, be good to yourself. Leave FGEN, tomorrow, first thing! FGEN is a business turnaround stock… it had historic terrible management, terrible FDA results… so, the stock today is a business plan bet… long-term, not daily… so, if you do not believe in the FGEN process, then stop complaining and Sell the stock, tomorrow. Simple as that.

0 · Reply

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 26 days ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 11:55 PM EDT - 4 weeks ago

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:02 PM EDT - 4 weeks ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 5 weeks ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 13, 2025, 8:22 AM EDT - 3 months ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

Jun 12, 2025, 4:02 PM EDT - 3 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 3 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 10:31 PM EDT - 4 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:02 PM EDT - 4 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 4 months ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 4 months ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 2, 2025, 4:05 PM EDT - 5 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 8:18 PM EDT - 6 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:05 PM EDT - 6 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 6 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 1:08 PM EST - 7 months ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

Feb 20, 2025, 6:40 AM EST - 7 months ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 7 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 9 months ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 8:38 PM EST - 10 months ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 4:05 PM EST - 10 months ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 11 months ago

FibroGen to Report Third Quarter 2024 Financial Results

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 6, 2024, 12:38 PM EDT - 1 year ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 3, 2024, 4:05 PM EDT - 1 year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 1 year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 2, 2024, 5:46 PM EDT - 1 year ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 5, 2024, 7:00 AM EST - 1 year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 1 year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Dec 9, 2023, 5:02 PM EST - 1 year ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 8:30 PM EST - 2 years ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results

Value10 Sep. 12 at 1:19 PM

2 · Reply

MaxMiamiFl Sep. 12 at 1:14 PM

$FGEN $11.30 to $14.00.....GO to $14 !!!! That's one of my exits.

0 · Reply

MaxMiamiFl Sep. 12 at 1:11 PM

$FGEN Lets go!

0 · Reply

Ctgf Sep. 12 at 4:03 AM

$FGEN At least this gives current management an opportunity to move forward. They are blaming everything on Peony Yu, whereas I expect that previous CEO Neff created this toxic environment.

2 · Reply

Red6213 Sep. 11 at 5:43 PM

4 · Reply

DipnRiptrader Sep. 11 at 5:02 PM

$FGEN Adding some of this. Ideally want a lower price but think this will do well overall.

1 · Reply

Value10 Sep. 11 at 4:43 PM

$FGEN Really Nice Volume… came in all at once… pushed it up.

1 · Reply

MaxMiamiFl Sep. 11 at 12:58 PM

$FGEN Nothing new. same red BS

0 · Reply

NVDAMillionaire Sep. 11 at 6:26 AM

1 · Reply

Value10 Sep. 9 at 8:27 PM

0 · Reply

Hanse76 Sep. 9 at 5:00 PM

$FGEN great to know

1 · Reply

MaxMiamiFl Sep. 9 at 4:22 PM

$FGEN from 0-10 what did they say that was importan= -0. Nothing, just bla bla bla bla bla bla what a waste of time

1 · Reply

MaxMiamiFl Sep. 9 at 3:31 PM

$FGEN MERGE/SELL!!!!!!!!!!!!!!!

1 · Reply

ARKADIY_PARAVOZOV Sep. 9 at 1:52 PM

$FGEN It's funny, only 418 shares were sold and an increase of 5.27%. Apparently, no one wants to sell.

0 · Reply

ARKADIY_PARAVOZOV Sep. 8 at 5:38 PM

$FGEN Look at how many buyers there are in August and how many sellers there are. Vanguard funds bought almost 5% of the company. I may be wrong, please correct me if I'm wrong. Buyers https://fintel.io/sob/us/fgen Sellers https://fintel.io/sos/us/fgen

1 · Reply

MaxMiamiFl Sep. 8 at 4:42 PM

$FGEN dammmmm 8% down for no reason

3 · Reply

ARKADIY_PARAVOZOV Sep. 8 at 2:22 PM

$FGEN either a partnership or a sale of the company, I don't see any other sober options. And tomorrow the director has to tell about it or hint at it.

2 · Reply

MaxMiamiFl Sep. 8 at 1:30 PM

$FGEN Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. (lets see what he says).

0 · Reply

Value10 Sep. 8 at 1:06 PM

$FGEN At this point, now that FGEN is under NO forced pressure on the NASDAQ share price or Debt terms / obligation… FGEN can finally negotiate without appearing vulnerable. Today, FGEN can finally and calmly have negotiations to either Sell-outright or partner with a large Pharma who will pay for the R & D plus additional milestone payments to FGEN. FGEN had to do the Reverse Split 25-1, and had to Sell China, and had to cut all expenses… cuz they had NO credibility and NO leverage to negotiate. Now, just give them a minute to exhale and negotiate.

3 · Reply

Waikiki2010 Sep. 8 at 12:46 PM

$FGEN The positive here is that the company has the financing to develop the phase 3 for Roxadustad in the US and to continue with FG 3246 , once any of these is approved or close to be approved PPS will explode and at least Roxa is expected to implement its last step for early next year , all these financial obligations are for 2028, more than 3 years from today so there is plenty of time to deal with them. IMO.

2 · Reply

Waikiki2010 Sep. 8 at 1:05 AM

$FGEN The Nova Quest deal. https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-50-million-royalty-monetization-financing#:~:text=$50%20million%20cash%20upfront%20in,to%20the%20global%20patient%20community.%E2%80%9D

2 · Reply

MaxMiamiFl Sep. 7 at 1:34 PM

$FGEN that second debt has me worried.

1 · Reply

Market Cap	50.27M
Revenue (ttm)	29.62M
Net Income (ttm)	-47.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-160.63%
Debt to Equity Ratio	-0.36

Volume	13,100
Avg Vol	54,406
Day's Range	N/A - N/A
Shares Out	4.04M
Stochastic %K	71%
Beta	0.76
Analysts	Sell
Price Target	$43.00